氘可来昔替尼(Deucravacitinib)能有效治病吗？

Introduction: Deucravacitinib is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Janus kinase functions as a homo or heterodimer in the JAK-STAT pathway. TYK2 pairs with JAK1 to mediate multiple cytokine pathways and pairs with JAK2 to transmit signals. The specific mechanism between inhibition of the TYK2 enzyme and therapeutic efficacy in the treatment of adult patients with moderate to severe plaque psoriasis is currently unclear.

Can the generic version of Deucravacitinib also be effective in treating diseases?

There are also generic drugs officially on the market, such as the generic version of Deucravacitinib produced by Ziska Pharmaceutical Factory in Bangladesh. Generic version of deucravacitinib has shown promising efficacy in the treatment of moderate to severe plaque psoriasis. Generic drugs need to be approved by relevant departments before they can be put on the market. Their drug ingredients, mechanism of action, efficacy, etc. are basically the same as the original drugs, and they can also effectively treat related diseases.

Deuterated coxitinib improves the symptoms of psoriasis by regulating the function of immune cells and reducing inflammatory responses. In clinical studies, deuterated colexitinib can significantly reduce scaly and erythematous lesions on the patient's body surface, relieve itching, and improve their quality of life. The generic version of deuterated colexitinib is effective in the treatment of psoriasis and has good safety and tolerability. The specific efficacy and safety need to be determined based on individual circumstances and physician evaluation.

Efficacy of Deucravacitinib

In a pivotal phase 3 POETYK PSO-1 and OETYK It was studied in the PSO-2 clinical trials, which demonstrated that once-daily deuterated colexitinib was superior to placebo and twice-daily apremilast in 1,684 patients 18 years and older with moderate-to-severe plaque psoriasis. Efficacy of deuterated colexitinib over placebo and apremilast was demonstrated at both 16 and 24 weeks, and responses with deuterated colexitinib were sustained for 52 weeks.

How to take Deucravacitinib

The recommended dose of Deucravacitinib is 6 mg orally once a day. It can be taken with or without food. It is recommended to swallow the tablet whole and do not crush, cut or chew the tablet. Patients should be evaluated for active and latent tuberculosis (TB) infection before treatment with deuterated colexitinib. If positive, antituberculosis treatment should be initiated before treatment with deuterated colexitinib.

Strictly follow your doctor's instructions when using deuterated colexitinib, and contact your doctor promptly if any problems or adverse reactions occur.